376 related articles for article (PubMed ID: 27184139)
1. GnRH antagonist rescue protocol combined with cabergoline versus cabergoline alone in the prevention of ovarian hyperstimulation syndrome: a randomized controlled trial.
Fouda UM; Sayed AM; Elshaer HS; Hammad BE; Shaban MM; Elsetohy KA; Youssef MA
J Ovarian Res; 2016 May; 9(1):29. PubMed ID: 27184139
[TBL] [Abstract][Full Text] [Related]
2. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles.
Toftager M; Bogstad J; Bryndorf T; Løssl K; Roskær J; Holland T; Prætorius L; Zedeler A; Nilas L; Pinborg A
Hum Reprod; 2016 Jun; 31(6):1253-64. PubMed ID: 27060174
[TBL] [Abstract][Full Text] [Related]
3. The prevention of ovarian hyperstimulation syndrome.
Corbett S; Shmorgun D; Claman P; ;
J Obstet Gynaecol Can; 2014 Nov; 36(11):1024-1033. PubMed ID: 25574681
[TBL] [Abstract][Full Text] [Related]
4. GnRH antagonist administered twice the day before hCG trigger combined with a step-down protocol may prevent OHSS in IVF/ICSI antagonist cycles at risk for OHSS without affecting the reproductive outcomes: a prospective randomized control trial.
Prapas Y; Ravanos K; Petousis S; Panagiotidis Y; Papatheodorou A; Margioula-Siarkou C; Iuliano A; Gullo G; Prapas N
J Assist Reprod Genet; 2017 Nov; 34(11):1537-1545. PubMed ID: 28776117
[TBL] [Abstract][Full Text] [Related]
5. Laparoscopic ovarian drilling versus GnRH antagonist combined with cabergoline as a prophylaxis against the re-development of ovarian hyperstimulation syndrome.
Seyam E; Hefzy E
Gynecol Endocrinol; 2018 Jul; 34(7):616-622. PubMed ID: 29334275
[TBL] [Abstract][Full Text] [Related]
6. Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG.
Seyhan A; Ata B; Polat M; Son WY; Yarali H; Dahan MH
Hum Reprod; 2013 Sep; 28(9):2522-8. PubMed ID: 23633553
[TBL] [Abstract][Full Text] [Related]
7. Low dose human chorionic gonadotropin administration at the time of gonadotropin releasing-hormone agonist trigger versus 35 h later in women at high risk of developing ovarian hyperstimulation syndrome - a prospective randomized double-blind clinical trial.
Engmann LL; Maslow BS; Kaye LA; Griffin DW; DiLuigi AJ; Schmidt DW; Grow DR; Nulsen JC; Benadiva CA
J Ovarian Res; 2019 Jan; 12(1):8. PubMed ID: 30684970
[TBL] [Abstract][Full Text] [Related]
8. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
Engmann L; DiLuigi A; Schmidt D; Nulsen J; Maier D; Benadiva C
Fertil Steril; 2008 Jan; 89(1):84-91. PubMed ID: 17462639
[TBL] [Abstract][Full Text] [Related]
9. A simplified universal approach to COH protocol for IVF: ultrashort flare GnRH-agonist/GnRH-antagonist protocol with tailored mode and timing of final follicular maturation.
Orvieto R
J Ovarian Res; 2015 Nov; 8():69. PubMed ID: 26536862
[TBL] [Abstract][Full Text] [Related]
10. Comparison of GnRH agonists and antagonists in assisted reproduction cycles of patients at high risk of ovarian hyperstimulation syndrome.
Ragni G; Vegetti W; Riccaboni A; Engl B; Brigante C; Crosignani PG
Hum Reprod; 2005 Sep; 20(9):2421-5. PubMed ID: 15890731
[TBL] [Abstract][Full Text] [Related]
11. Prediction of Ovarian Hyperstimulation Syndrome in Patients Treated with Corifollitropin alfa or rFSH in a GnRH Antagonist Protocol.
Griesinger G; Verweij PJ; Gates D; Devroey P; Gordon K; Stegmann BJ; Tarlatzis BC
PLoS One; 2016; 11(3):e0149615. PubMed ID: 26950065
[TBL] [Abstract][Full Text] [Related]
12. Towards an optimal luteal support modality in agonist triggered cycles: a randomized clinical trial.
Elgindy EA; Sibai H; Mostafa MI; Gibreel A; Darwish E; Maghraby H
Hum Reprod; 2018 Jun; 33(6):1079-1086. PubMed ID: 29562260
[TBL] [Abstract][Full Text] [Related]
13. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients.
Humaidan P; Polyzos NP; Alsbjerg B; Erb K; Mikkelsen AL; Elbaek HO; Papanikolaou EG; Andersen CY
Hum Reprod; 2013 Sep; 28(9):2511-21. PubMed ID: 23753114
[TBL] [Abstract][Full Text] [Related]
14. Prevention of ovarian hyperstimulation syndrome in GnRH agonist IVF cycles in moderate risk patients: randomized study comparing hydroxyethyl starch versus cabergoline and hydroxyethyl starch.
Matorras R; Andrés M; Mendoza R; Prieto B; Pijoan JI; Expósito A
Eur J Obstet Gynecol Reprod Biol; 2013 Oct; 170(2):439-43. PubMed ID: 23932181
[TBL] [Abstract][Full Text] [Related]
15. Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome.
D'Angelo A; Amso NN; Hassan R
Cochrane Database Syst Rev; 2017 May; 5(5):CD002811. PubMed ID: 28535578
[TBL] [Abstract][Full Text] [Related]
16. GnRH-agonist ovulation trigger in patients undergoing controlled ovarian hyperstimulation for IVF with ultrashort flare GnRH-agonist combined with multidose GnRH-antagonist protocol.
Orvieto R; Nahum R; Zohav E; Liberty G; Anteby EY; Meltcer S
Gynecol Endocrinol; 2013 Jan; 29(1):51-3. PubMed ID: 22857268
[TBL] [Abstract][Full Text] [Related]
17. Cabergoline versus calcium infusion in the prevention of ovarian hyperstimulation syndrome: a randomised controlled study.
Fouda UM; Elshaer HS; Youssef GG; Hanafy A; Mehrem WM; Youssef MA; Farouk M; Nabil H
J Obstet Gynaecol; 2022 Jan; 42(1):122-126. PubMed ID: 34270379
[TBL] [Abstract][Full Text] [Related]
18. GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis.
Griesinger G; Diedrich K; Devroey P; Kolibianakis EM
Hum Reprod Update; 2006; 12(2):159-68. PubMed ID: 16254001
[TBL] [Abstract][Full Text] [Related]
19. GnRH antagonist rescue in high responders at risk for OHSS results in excellent assisted reproduction outcomes.
Hill MJ; Chason RJ; Payson MD; Segars JH; Csokmay JM
Reprod Biomed Online; 2012 Sep; 25(3):284-91. PubMed ID: 22796230
[TBL] [Abstract][Full Text] [Related]
20. Pregnancy and neonatal outcomes following luteal GnRH antagonist administration in patients with severe early OHSS.
Lainas GT; Kolibianakis EM; Sfontouris IA; Zorzovilis IZ; Petsas GK; Lainas TG; Tarlatzis BC
Hum Reprod; 2013 Jul; 28(7):1929-42. PubMed ID: 23624582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
